Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
To accelerate the development of next-generation radioconjugates to treat cancer
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
_Rupak_Singla_256_384.jpg)
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Subscribe To Our Newsletter & Stay Updated
